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EDITOR’S PICK
Direct oral anticoagulants (DOAC) provide clinicians with a valuable method for the  
prevention and treatment of thrombotic events. However, DOAC also expose patients to the 
risk of bleeding or major bleeding, which can lead to major adverse events as a result of their 
inappropriate use. This article by Vornicu et al. highlights the various aspects that require 
consideration in order to minimise the incidence of these adverse events and points to the 
approaches available to ensure this can be done effectively. The article also provides important 
practical guidance in specific situations where DOAC are vulnerable to mismanagement. 
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ABSTRACT
Direct oral anticoagulants (DOAC) are used in several indications for the prevention and treatment 
of thrombotic events. As highlighted by data from clinical trials and case studies, all DOAC carry the risk 
of bleeding despite careful selection and patient management. Previous publications have demonstrated 
the limited knowledge of many physicians concerning the indications for, and correct management of, 
these anticoagulants. Health institutions should develop risk minimisation strategies and educational 
materials to prevent major adverse events related to DOAC administration. Major bleeding events are 
reported in clinical practice and specific antidotes are emerging from Phase III trials. Some antidotes 
are licensed but their high cost might limit routine use. We therefore illustrate approaches and tools 
that can help physicians prescribe DOAC appropriately. We focus on screening for modifiable bleeding 
risk factors and adapting doses according to the individual benefit-risk profile. We also provide 
recommendations on managing a missed dose, switching, bridging, and resumption.
Keywords: Prevention, bleeding, direct oral anticoagulants (DOAC).
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INTRODUCTION
Bleeding events have been reported in all 
the major clinical trials comparing direct oral 
anticoagulants (DOAC) with other anticoagulants 
despite regular monitoring of adverse events, 
strong medication adherence, and careful 
patient selection.1-4
Large randomised trials comparing bleeding risks 
of different DOAC are not available as DOAC have 
always been compared with warfarin, low molecular 
weight heparin (LMWH), and antiplatelet agents. 
When DOAC were prescribed at prophylactic 
doses in orthopaedic surgery, rates of bleeding 
were similar to LMWHs.5 When DOAC were 
prescribed for patients with non-valvular atrial 
fibrillation (NVAF) or venous thromboembolism 
(VTE), a recent meta-analysis showed a lower 
rate of fatal bleeding and case-fatality of major 
bleeding (MB) events for DOAC than with 
warfarin.6 Another meta-analysis showed that 
patients with a creatinine clearance (CrCl) 
between 50–80 mL/min who received DOAC 
had significantly fewer MB events than 
those receiving vitamin K antagonists (VKA). 
For patients with CrCl <50 mL/min, the difference 
in MB was not statistically significant, but using 
indirect comparisons, apixaban was associated with 
significantly fewer MB episodes than other DOAC.7 
Post-marketing surveillance registries provide 
real-world data on the safety and efficacy of 
DOAC. A retrospective cohort study of Medicare 
beneficiaries with NVAF found a higher incidence 
of MB with dabigatran than with warfarin, 
regardless of anatomical site.8 A smaller Italian 
cohort study revealed a safe profile of either 
110 mg or 150 mg dabigatran twice daily (bid), 
regarding fatal bleeding in patients at high risk of 
haemorrhage and thromboembolism.9 The Dresden 
New Oral Anticoagulants (NOAC) registry found 
that the routine safety profile of dabigatran 
etexilate (DE) was no worse than that reported 
in the RE-LY trial even if selection bias might 
exist.10 The Danish national registry found a 
higher bleeding rate in previous VKA users than 
VKA-naïve patients. This observation may reflect 
patient selection and ‘drug switching’ practices.11 
Concerning rivaroxaban, a large observational 
study showed that the MB rate was generally 
consistent with registration trial results and that 
fatal bleeds were rare.12 The MB rate with 
rivaroxaban from the Dresden NOAC registry was 
lower than that for VKA.13 However, the ROCKET 
AF trial identified age, sex, diastolic blood pressure, 
prior gastrointestinal bleeding, prior aspirin 
use, and anaemia as clinically relevant factors 
associated with MB risk with rivaroxaban and 
VKA.14 This review aims to discuss strategies 
to prevent DOAC-related bleeding in normal 
clinical practice.
HOW TO PREVENT MAJOR BLEEDING  
Various aspects of the management of patients 
treated with DOAC should be highlighted to 
reduce the incidence of MB.
Appropriate Use of Direct  
Oral Anticoagulants 
Off-label use or misuse 
The off-label use or misuse of DOAC means use 
outside of approved indication, at an inappropriate 
dose, or an inappropriate choice of DOAC 
according to patient characteristics. Inappropriate 
use is frequent (occurring in 8–49% of patients) 
and may cause infra or supra-therapeutic 
anticoagulation carrying risks of thromboembolism 
or severe, even fatal bleeding (Table 1).11,15-19 A recent 
publication indicated a significant risk for patients 
related to lack of physicians’ knowledge about 
DOAC and highlighted the need for additional 
education and training.20
Renal function 
Renal failure is the most common risk factor 
associated with bleeding in elderly patients, and 
should therefore be assessed before initiating 
DOAC and during treatment.21 The updated 
European Heart Rhythm Association (EHRA) 
practical guide on the use of DOAC suggests that 
renal function should be checked every 6 months 
in patients >75–80 years (especially those on DE 
or edoxaban), and in frail patients.22 The proposed 
recheck interval (in months) is the CrCl divided 
by 10, if the CrCl is <60 mL/min. More frequent 
checks are recommended in patients with 
conditions that might affect renal function. 
In clinical trials of DOAC for NVAF, drug eligibility 
and dosing were determined using the Cockcroft– 
Gault equation to estimate CrCl. The modification 
of diet in renal disease equation (used to estimate 
glomerular filtration rate) tends, at low estimate 
glomerular filtration rate values, to overestimate 
renal function compared with the Cockcroft–Gault 
equation.23,24 This overestimation may lead to 
incorrect decisions about eligibility or dose.
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Table 1: Summary of pharmacokinetic properties, indication, and dose regimens of direct oral 
anticoagulants in the European Union.29,35,46,54,62-83
Dabigatran Rivaroxaban Apixaban Edoxaban
Target Factor lla Factor Xa Factor Xa Factor Xa
Prodrug Yes No No No 
Tmax (hours) 1.5–3.0 2.0–4.0 3.0–4.0 1.0–2.0
Distribution  
volume (L)
60–70 ±50 23 107
Half-life (hours) 11: healthy individuals 
12–13: elderly
5–9: healthy individuals 
11–13: elderly
8–15: healthy 
individuals
10–14
Bioavailability 3–7% pH sensitive 2.5–10 mg dose: 
80–100%  
(fasting/fed) 
15–20 mg dose: 66% 
(fasting) ± 100% (fed)
±50% 62%
Protein binding 35% >90% 87% 55%
Metabolism Conjugation CYP-dependent 
and independent 
mechanisms
CYP-dependent 
mechanisms
CYP-dependent (<5%) 
and independent 
mechanisms (<10%)
Active metabolites Yes: glucuronide 
conjugates
No No Yes (<15%)
Elimination 80% renal 33% unchanged via the 
kidney
27% renal 50% renal
20% bile (glucuronide 
conjugation)
66% metabolised in 
the liver into inactive 
metabolites eliminated 
via the kidney (50%) or 
the colon (50%)
73% through the 
liver while the 
residue is excreted 
by the hepatobiliary 
route 
50% metabolism 
and biliary/intestinal 
excretion
Effects of food Tmax delayed; Cmax & 
AUC unchanged
Tmax delayed; Cmax & 
AUC increased (15–20 
mg)
Tmax delayed; Cmax & 
AUC unchanged
Cmax increased, but 
minimal effect on total 
exposure
CYP substrate No CYP3A4, CYP2J2 CYP3A4 CYP3A4 (<5%)
P-gp substrate DE: Yes Yes Yes Yes
Venous  
thromboembolism 
Prophylaxis
220 mg/day
(2 caps 110 mg qd) 
Cmax: 
 71 (35–162) ng/mL 
(mean; 25–75 PCTL) 
Cmin: 
 22 (13–36) ng/mL
(mean; 25–75 PCTL) 
150 mg/day  
(2 caps 75 mg qd)
 if CrCl 30–50  
mL/min, if >75 years, if 
verapamil, amiodarone, 
and quinidine  
THR: 28–35 days 
TKR: 10 days
10 mg/day
(1 tablet 10 mg qd) 
Cmax:  
125 (91–196) ng/mL 
(median; 5–95 PCTL) 
Cmin:
9 (1–38) ng/mL
(median; 5–95 PCTL)
THR: 5 weeks 
TKR: 2 weeks
5 mg/day
(1 tablet 2.5 mg bid) 
Cmax:  
77 (41–146) ng/mL 
(median; 5–95 PCTL) 
Cmin:  
51 (23– 109) ng/mL
(median; 5–95 PCTL)
THR: 32–38 days
TKR: 10 days
 (EU)
Bioavailability 
If DE capsules are opened, the bioavailability 
increases to 75% and the bleeding risk is greatly 
enhanced.25 Therefore, DE should not be given via 
a gastrostomy or jejunostomy and capsules should 
not be opened or crushed before administration. 
Rivaroxaban and apixaban have similar 
bioavailability when administered in crushed form 
mixed with apple sauce or water through a 
nasogastric tube or gastrostomy.26,27 To the best of 
our knowledge, there are currently no data 
available for edoxaban.
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Table 1 continued.
Dabigatran Rivaroxaban Apixaban Edoxaban
Non-valvular  
atrial  
fibrillation*
300 mg/day 
(1 caps 150 mg bid) 
Cmax:  
175 (117-275) ng/mL 
(mean; 25–75 PCTL)  
Cmin: 91 (61-143-200) 
ng/mL (mean; 
25–75–90 PCTL)
220 mg/day   
(1 caps 110 mg bid) 
 if >80 years  
or verapamil
20 mg/day
(1 tablet 20 mg qd) 
Cmax:  
249 (184–343) ng/mL 
(mean; 5–95 PCTL) 
Cmin: 
44 (12–137) ng/mL 
(mean; 5–95 PCTL)  
15 mg/day  
(1 tablet 15 mg qd)  
 if CrCl between  
15-49 mL/min  
Cmax: 
229 (178–313) ng/mL
(mean: 5–95 PCTL)
Cmin:  
57 (18–136) ng/mL 
(mean; 5–95 PCTL)
10 mg/day
 (1 tablet 5 mg bid)
Cmax:  
171 (91–321) ng/mL 
(median; 5–95 PCTL) 
Cmin:  
103 (41–230) ng/mL 
(median; 5–95 PCTL) 
5 mg/day
(1 tablet 2.5 mg bid) 
 If at least 2 of the 
following conditions: 
≥80 years, ≤60 kg or 
serum creatinine ≥  
1.5 mg/dL;  
 Or if CrCl 15-29 
mL/min
Cmax:  
123 (69–221) ng/mL 
(median; 5–95 PCTL) 
Cmin:  
79 (34–162) ng/mL 
(median; 5–95 PCTL)
60 mg/day
(1 tablet 60 mg qd) 
Cmax: 
+/-170 (165–195)  
ng/mL
(median; IQR)
Cmin:  
36 (19–62) ng/mL 
(median; IQR)  
30 mg/day
(1 tablet 30 mg qd)  
if CrCl between 15–50 
mL/min,  
≤60 kg or 
concomitant use 
of dronedarone, 
erythromycin, 
ketoconazole, 
ciclosporin  
Cmin:
27 (15–45) ng/mL 
(median; IQR)
Venous  
thromboembolism 
treatment
300 mg/day 
(1 caps 150 mg bid)  
after at least 5 
days of parenteral 
anticoagulants  
Cmax: 
175 (117–275) ng/mL 
(mean; 25–75 PCTL) 
Cmin: 
60 (39–95–146)  
ng/mL (mean;  
25–75–90 PCTL)
220 mg/day
(1 caps 110 mg bid)  if 
>80 years or verapamil
Treatment phase: 
30 mg/day
(1 tablet 15 mg bid) 
for 21 days  
 followed by  
20 mg/day  
(1 tablet 20 mg qd)  for 
3–6 months  
Cmax:  
270 (189–419) ng/mL
(mean; 5–95 PCTL)
Cmin:  
26 (6–87) ng/mL 
(mean; 5–95 PCTL)  
15 mg/day 
(1 tablet 15 mg qd) 
 if CrCl between 15–
49 mL/min and the risk 
of bleeding outweighs 
the risk of recurrent 
DVT or PE
Treatment phase: 
20 mg/day 
(2 tablet 5 mg bid) 
for 7 days  
Cmax:
251 (111–572) ng/mL 
(median; 5–95 PCTL) 
Cmin:  
120 (41–335) ng/mL 
(median; 5–95 PCTL) 
 followed by  
10 mg/day 
(1 tablet 5 mg bid) 
for 3–6 months
Cmax:  
132 (59–302) ng/mL 
(median; 5–95 PCTL) 
Cmin:  
63 (22–177) ng/mL 
(median; 5–95 PCTL)
If high risk of 
recurrent DVT or PE: 
5 mg/day 
(1 tablet 2.5 mg bid)  
after 6 months 
treatment 
60 mg/day
(1 tablet 60 mg qd)  
after at least 5 
days of parenteral 
anticoagulant 
treatment 
 
30 mg/day  
(1 tablet 30 mg qd) 
 if CrCl between  
15–50 mL/min, BW 
≤60 kg or concomitant 
use of dronedarone, 
erythromycin, 
ketoconazole, 
ciclosporin
Prevention of  
athero-thrombotic 
events after 
ACS with 
elevated cardiac 
biomarkers
 5 mg/day
(1 tablet 2.5 mg bid)
with ASA (75–100 mg) 
or, ASA + clopidogrel 
(75 mg) or ticlopidine
Cmax:
46 (28–70) ng/mL
(median; 5–95 PCTL)
Cmin:
17 (6–37) ng/mL
(median; 5–95 PCTL)
 
Tmax: time to reach peak concentration; Cmax: peak concentration; AUC: area under the curve; CYP3A4: 
cytochrome P450 isozyme 3A4; P-gp: P-glycoprotein; BRCP: breast cancer resistance protein; 
caps: capsule; qd: once daily; bid: twice daily; CrCl: creatinine clearance; DVT: deep-vein thrombosis; 
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Table 1 continued.
Patient body weight 
There is evidence that anticoagulant clearance 
rates increase with body weight, however optimal 
dosing strategies for DOAC in obese patients 
remain unknown.28 In the RE-LY study, dabigatran 
concentrations tended to increase with decreasing 
body weight.28 Close clinical surveillance is 
recommended by several authorities because of 
limited clinical experience in these populations.29,30 
Kubitza et al.31 showed that rivaroxaban peak 
concentration (Cmax) was increased by 24% in 
subjects weighing ≤50 kg while the area under the 
curve (AUC) was unaffected (difference was <25%) 
by body weight resulting in a small (15%) increase 
in prolongation of prothrombin time, which was 
not considered to be clinically relevant. Similarly 
to dabigatran, no dose adjustment is currently 
proposed by the European or American agencies.32 
Regarding apixaban, a 30% and 20% increase in 
Cmax and AUC, respectively, have been reported 
in patients weighing <50 kg.33 Since body weight 
seems to have a modest effect on apixaban 
exposure, the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) 
recommend dose adjustment in patients weighing 
<60 kg (2.5 mg bid instead of 5 mg bid) in the 
presence of additional risk factors, namely age 
≥80 years or serum creatinine >1.5 mg/dL.34,35 
Dose adjustment in patients weighing <60 kg is 
also recommended for edoxaban (30 mg once 
daily since Cmax and AUC in patients with low body 
weight (median 55 kg) were increased by 
40% and 13%, respectively, compared with 
patients with high body weight (median 84 kg) 
in a population pharmacokinetic analysis of the 
ENGAGE AF-TIMI 48 study in NVAF.36
Patients with impaired hepatic function  
The manufacturer’s recommendations for DOAC in 
patients with impaired hepatic function are based 
on both Child–Pugh classification and liver-related 
exclusion criteria applied in clinical trials (elevated 
liver enzymes [aspartate transaminase/alanine 
transaminase] >2-times the upper limit of normal 
or total bilirubin ≥1.5-times the upper limit of 
normal).37 The EMA contraindicates the use of 
dabigatran in patients with hepatic impairment or 
liver disease expected to have any impact 
on survival.29 
In contrast to dabigatran, liver metabolism is an 
important route of elimination for FXa inhibitors. 
Approximately two-thirds of the administered 
rivaroxaban dose is metabolised by the liver via 
CYP3A4, 2J2, and CYP-independent mechanisms 
into inactive metabolites.32 Apixaban undergoes 
liver metabolism mainly via CYP3A4/5, but 
other isoenzymes are also involved, while 
edoxaban is metabolised via carboxylesterase-1 
hydrolysis, conjugation, or oxidation by CYP3A4/5 
(<10%). Therefore, the EMA contraindicates their 
use in cases of hepatic disease associated with 
coagulopathy and clinically relevant bleeding risk. 
Apixaban and edoxaban are not recommended in 
patients with severe hepatic impairment, 
rivaroxaban is also contraindicated in cirrhotic 
patients with Child–Pugh B/C. Although one 
limited study showed a similar bleeding risk in 
Child–Pugh A/B cirrhosis patients treated with 
apixaban or rivaroxaban compared with traditional 
anticoagulants, further evaluations and larger 
studies are needed to better inform clinicians’ 
decision-making.38
Drug interactions 
In addition to these specific populations, 
DOAC also interact with P-glycoprotein substrates 
and CYP3A4 inhibitors, which may greatly 
increase their plasma concentrations, and hence, 
bleeding risks. Table 2 summarises drug-drug 
interactions reported in the literature as well 
as recommendations for dose adaptation 
and contraindications for the EMA and FDA 
prescribing guidelines.22,39,40 As there is an 
increased risk of bleeding, DOAC should be used 
with caution if a concomitant use of antiplatelet 
agents is indicated29,32,35 and non-steroidal 
anti-inflammatory drugs (NSAID) should be 
avoided if possible.28,31,39 Concomitant use with 
PE: pulmonary embolism; THR: total hip replacement; TKR: total knee replacement; ASA: acetylsalicylic 
acid; ACS: acute coronary syndrome; Cmax and Cmin: peak and trough concentrations providing from 
the clinical trials; PCTL: percentiles; IQR: interquartile range; BW: body weight; DE: dabigatran etexilate.
 = off-label; EU: European Union.
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Table 2: Summary of drug-drug interactions with available recommendations for dose adaptation 
or contraindications by the competent authorities.22,39,40,83
Dabigatran 
P-gp substrate
Rivaroxaban
P-gp and 
CYP3A4/2J2 
substrate
Apixaban
P-gp and 
CYP3A4/5 
substrate
Edoxaban
P-gp substrate
Molecule Mechanism
Antiarrhythmics
Dronedarone P-gp and  
CYP3A4 inhibitor
AUC: +114%   
(400 mg: single 
dose)*
Minor effect  
(use with  
caution if CrCl  
15-50 mL/min)†
No data yet Cmax: +46%  
AUC: +85%***
AUC: +136%  
(400 mg: 
multiple doses)
Quinidine P-gp
competition
AUC: +53% 
(1,000 mg: single 
dose)**
Minor effect 
(use with caution if 
CrCl  
15–50 mL/min)
No data yet AUC: +77%
Cmax: +85%  
(300 mg: 
multiple doses)
Verapamil P-gp  
competition and 
weak CYP3A4 
inhibitor
AUC: +18% 
(120 mg IR: single 
dose taken  
2 hours after DE 
intake)**/***
Minor effect 
(use with caution if 
CrCl 15–50 mL/min)
No data yet AUC and Cmax: 
+53% (240 mg: 
multiple doses)
AUC: +143% 
(120 mg IR:  
single dose,  
1 hour before DE 
intake)**/***
Cmax: +12% 
(120 mg IR: single 
dose taken 2 
hours after DE 
intake)**/***
Cmax: +179% 
(120 mg IR:  
single dose,  
1 hour before DE 
intake)**/***
Amiodarone P-gp competition AUC: +58% 
(600 mg:  
single dose)**
Minor effect 
(use with caution if 
CrCl 15–50 mL/min)
No clinically 
relevant effect
AUC: +40%
Cmax: +66% (400 
mg: single dose)
any other anticoagulant is strictly contraindicated, 
except during switching procedures from DOAC 
to VKA or when unfractionated heparin (UFH) 
is given at doses necessary to maintain an open 
central venous or arterial catheter.29
Screening for Bleeding Risk Factors  
Non-modifiable and potentially reversible clinical 
features associated with higher bleeding risks 
must be carefully identified when initiating DOAC 
therapy and assessed regularly throughout 
treatment. Various risk stratification scores can 
help clinical decision-making.41,42 The bleeding risk 
score HAS-BLED has shown better performance 
than the HEMORR(2)HAGES and ATRIA risk scores 
in predicting MB in anticoagulated AF patients.41 
A value ≥3 indicates a high risk for 
haemorrhage and suggests review and correction 
of modifiable risk factors (hypertension, renal/ 
hepatic impairment, alcohol excess, concomitant 
use of non-steroidal anti-inflammatory drugs, 
antiplatelet agents, or selective serotonin reuptake 
inhibitors). The simple five-element ORBIT AF 
bleeding risk score (older age [>75 years], reduced 
haemoglobin/haematocrit history of anaemia, 
bleeding history, insufficient kidney function, 
and treatment with antiplatelet agents) had the 
best ability to predict MB in patients with NVAF 
compared with HAS-BLED and ATRIA risk scores.43 
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Table 2 continued.
Dabigatran 
P-gp substrate
Rivaroxaban
P-gp and 
CYP3A4/2J2 
substrate
Apixaban
P-gp and 
CYP3A4/5 
substrate
Edoxaban
P-gp substrate
Molecule Mechanism
Diltiazem P-gp and 
CYP3A4 inhibitor
No effect Minor effect 
(use with caution if 
CrCl 15–50 mL/min)
AUC: +40% No data yet
Antianginal/antihypertensive drugs
Ranolazine P-gp and  
CYP3A4 inhibitor
No data yet Minor effect
(use with caution if 
CrCl 15–50 mL/min)
No data yet No data yet 
Felodipine P-gp and  
CYP3A4 inhibitor
No data yet Minor effect
(use with caution if 
CrCl 15–50 mL/min)
No data yet No data yet
Anti-inflammatory
Naproxen P-gp competition No data yet AUC: +10% (500 
mg)
Cmax: +61%
AUC: +55%
(500 mg)
No effect, but 
pharmacod 
namically 
increased 
bleeding time
Antihypercholesterolemiant
Atorvastatin P-gp and 
CYP3A4 
substrate
AUC: +18% No effect No PK data yet No effect
Antimycotic
Ketoconazole P-gp and 
CYP3A4 inhibitor
AUC: +138% 
(400 mg: single 
dose)*
Cmax: +72% (400 
mg: single dose †
Cmax: +62%
(400 mg 
multiple doses)†
Cmax: +89%***
(400 mg 
multiple doses)
AUC: +153% 
(400 mg: 
multiple doses)
AUC: +158% (400 
mg: single dose)†
AUC: +100% 
(400 mg 
multiple doses)†
AUC: +87% 
*** (400 mg 
multiple doses)
Itraconazole P-gp and 
CYP3A4 inhibitor
No data yet* No data yet, but 
similar results than 
ketoconazole are 
expected†
No data yet, 
but similar 
results than 
ketoconazole 
are expected†
No data yet
Voriconazole P-gp and 
CYP3A4 inhibitor
No data yet No data yet
Posaconazole P-gp and 
CYP3A4 inhibitor
No data yet*** No data yet† No data yet
Fluconazole CYP3A4 inhibitor No data yet - 
supposed  
no effect
Cmax: +28%
AUC: +42%
No data yet No data yet
Antibacterial
Clarithromycin P-gp and 
CYP3A4 inhibitor
Cmax: +49% No data yet No data yet
AUC: +60% AUC: +54%  
(500 mg multiple 
doses)
Azithromycin P-gp and 
CYP3A4 inhibitor
No data yet Minor effect 
(use with caution if 
CrCl 15–50 mL/min)
No data yet No data yet
Erythromycin P-gp and 
CYP3A4 inhibitor
No data yet AUC: +34% (500 
mg multiple doses)
No data yet Cmax: +68%***
AUC: +85%***
Rifampicin P-gp and 
CYP3A4 inducer
Cmax: -65,5%†
AUC: -67%†
(600 mg: 
multiple doses)
AUC: -50%† AUC: -54%† AUC: -35% 
but with 
compensatory 
increase of active 
metabolite (avoid 
if possible)
HEMATOLOGY  •  July 2016   EMJ  EUROPEAN MEDICAL JOURNAL HEMATOLOGY  •  July 2016   EMJ  EUROPEAN MEDICAL JOURNAL 84 85
Table 2 continued.
*Contraindicated by the European Medicines Agency (EMA). 
**The EMA recommends dose reduction for dabigatran: from 220 mg qd to 150 mg qd in prevention of 
VTE in joint replacement. 
***The EMA recommends dose reduction for dabigatran: from 150 mg bid to 110 mg bid) in patients with 
NVAF or VTE; and for edoxaban a dose reduction of 50% (30 mg qd) in patients with NVAF or VTE. 
†Concomitant treatment with these drugs are not recommended by the EMA.
NVAF: non-valvular arterial fibrillation; VTE: venous thromboembolism; P-gp: p-glycoprotein; 
CYP: cytochrome; AUC: area under the curve; CrCl: creatinine clearance; PK: pharmacokinetics; 
Cmax/Cmin: peak and trough concentrations providing from the clinical trials; qd: once daily; bid: 
twice daily; DE: dabigatran etexilate.
Dabigatran 
P-gp substrate
Rivaroxaban
P-gp and 
CYP3A4/2J2 
substrate
Apixaban
P-gp and 
CYP3A4/5 
substrate
Edoxaban
P-gp substrate
Molecule Mechanism
Protease inhibitors
Ritonavir P-gp and CYP 
3A4 inhibitor
No data yet† Cmax: +55%  
(600 mg multiple 
doses)†
No PK data 
but strong 
increase†
No data yet†
AUC: +153%  
(600 mg multiple 
doses)†
Immunosuppressor
Ciclosporine P-gp competition No data yet* AUC: +50% No data yet AUC: +73%***
Cmax: +74%
(500 mg  
single dose)
Tacrolimus P-gp competition No data yet† AUC: +50% No data yet No data yet
Screening for injuries (e.g. recent intracranial 
haemorrhage) and conditions (e.g. colon cancer) 
that may lead to MB is essential before starting 
DOAC therapy. 
Particular attention should be paid to renal 
protective strategies for patients on dabigatran 
and edoxaban. These patients should be informed 
about the impact of concurrent medications 
(e.g. NSAID) or comorbidities (e.g. dehydration) 
on their renal function, which could lead to an 
enhanced and prolonged anticoagulant effect.
Adapting Direct Oral Anticoagulant Dosage  
to Individual Benefit-Risk Ratios 
Why and when? 
Several criteria should be taken into account when 
considering drug monitoring: 1) intra and 
2) inter-individual variability in plasma drug level, 
both justifying the identification of the optimal 
dose for the individual at the start of treatment, 
3) variability and reproducibility of the testing 
method, 4) correlation between drug level and 
clinical outcome, and 5) the therapeutic value of 
drug monitoring. 
DOAC demonstrate high intra and inter-individual 
variability depending on patients’ age, renal and 
hepatic function, drug-drug interactions, and 
body weight.44 While package inserts recommend 
dose adaptation according to the patient’s 
characteristics, they do not give guidance for 
patients with multiple interfering factors in whom 
a targeted plasma level cannot be reached. 
The importance of targeted plasma levels is 
supported by analysis of large trials (RE-LY and 
the ENGAGE-AF TIMI 48), which showed that 
plasma concentrations of dabigatran and edoxaban 
were correlated with the incidence of MB and 
thrombotic events.45-47 Although there are currently 
no published data for rivaroxaban and apixaban, 
data from the FDA Clinical Pharmacology 
and Biopharmaceutics Reviews (available at 
HEMATOLOGY  •  July 2016   EMJ  EUROPEAN MEDICAL JOURNAL HEMATOLOGY  •  July 2016   EMJ  EUROPEAN MEDICAL JOURNAL 86 87
Table 3: Current indication, clinical need, and required assay characteristics for the measurement of direct 
oral anticoagulants.49-51
Indication Emergent 
situation†
Information required Characteristic of  
the assay
Assays recommended††
Bleeding Yes Identifying above  
on-therapy levels 
• Sensitive 
(qualitative and 
quantitative) 
• Rapid turn-
around time
• Specific coagulation tests 
(i.e. dTT, ECA - dabigatran; 
chromogenic anti-Xa - direct 
FXa inhibitors)
• Global coagulation tests (i.e. 
PT (rivaroxaban - edoxaban) - 
aPTT (dabigatran) or dRVVT)
Elective invasive 
procedure
No Excluding on-therapy 
level and ensure safe 
procedure‡
• Sensitive 
(qualitative and 
quantitative)
• Accurate
• Specific coagulation tests 
(i.e. dTT, ECA - dabigatran; 
chromogenic anti-Xa - direct 
FXa inhibitors)
• Thrombin time (dabigatran)
Urgent invasive 
procedure
Yes Excluding on-therapy 
levels and ensure safe 
procedure‡
• Sensitive 
(qualitative and 
quantitative)
• Accurate
• Rapid turn-
around time
• Specific coagulation tests 
(i.e. dTT, ECA - dabigatran; 
chromogenic anti-Xa - direct 
FXa inhibitors)
• Global coagulation tests (i.e. 
PT (rivaroxaban edoxaban) - 
aPTT (dabigatran) or dRVVT)
• Thrombin time (dabigatran)
Thrombolysis Yes Exclude on-therapy 
drug level and ensure 
safe procedure
• Sensitive 
(qualitative and 
quantitative)
• Accurate
• Rapid turn-
around time
• Specific coagulation tests 
(i.e. dTT, ECA - dabigatran; 
chromogenic anti-Xa -  
direct FXa inhibitors)
• Thrombin time (dabigatran)
http://www.fda.gov) clearly suggest an association 
between drug exposure and safety outcomes. 
Thus, patients may benefit from individualised 
dose tailoring.
In addition, specific situations require an 
assessment of the intensity of anticoagulation to 
prevent bleeding and other complications. These 
include the peri-procedural management of urgent 
surgery or elective procedures, before thrombolysis 
or percutaneous coronary intervention, and 
bridging therapy. Patients on dual antiplatelet 
therapy added to DOAC could also benefit from 
a reduced posology to prevent bleeding.48 
How to handle and perform such measurements? 
Compared to VKA, the effect of DOAC on clotting 
tests varies greatly depending on the time 
between the last dose and blood sampling 
(Table 1).49 Therefore, the time of the last dose 
in relation to the blood sampling must be known in 
order to interpret the results of a particular test.
In ambulatory patients, regulatory documents 
only state thresholds associated with a risk of 
bleeding for dabigatran. The cut-offs proposed 
for apixaban, rivaroxaban, and edoxaban are 
based on the pharmacokinetic characteristics 
of these drugs where it is suggested that 
exceeding the highest percentile of a trough 
concentration carries a risk of bleeding. 
Regarding which test should be used, Table 3 
summarises recommendations depending on the 
situation and the drug. While limitations have been 
mentioned for routine coagulation tests such as 
prothrombin time, activated partial thromboplastin 
time, and even thrombin time,50,51 the aim of 
this comprehensive approach is to provide reliable 
options, even for laboratories where more specific 
tests are not available, to give physicians sufficient 
information to support their clinical decisions.
Dealing with Missed Doses 
If a missed dose is noticed within 6 hours of 
the correct time for dabigatran/apixaban or 
within 12 hours for edoxaban/rivaroxaban, patients 
should take the forgotten dose immediately. 
Beyond these times, the dose should be skipped 
and the next scheduled dose should be taken.22 
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A double dose should never be taken to make 
up for a missed dose except during the first 
21 days of rivaroxaban administration for VTE 
treatment, where two 15 mg tablets may be taken 
simultaneously if a dose is missed to ensure a 
total daily dose of 30 mg.32 
Adherence to Switching Procedures 
The correct timing of switching procedures is 
essential to avoid excessive anticoagulation due to 
additional effects and to reduce thromboembolic 
risk due to transitory low anticoagulation. 
This timing has been fixed for each DOAC taking 
into account the drug profile and trial protocols.52 
The Dresden NOAC registry reported that 25% of 
patients did not have an international normalised 
ratio (INR) measurement before switching from 
VKA to DE or rivaroxaban.53
Practically, when VKA are switched to DOAC, 
VKA should be discontinued and DOAC should be 
started as soon as the INR is ≤2 for dabigatran 
and apixaban, ≤2.5 for edoxaban, or ≤3 for 
rivaroxaban. The EMA recommends that for 
patients with a deep vein thrombosis, rivaroxaban 
should be initiated once the INR is ≤2.5.22
When DOAC are switched to VKA, DOAC should 
be administered concomitantly until the INR 
reaches an appropriate anticoagulation level. 
As DOAC can have an impact on the INR 
measurements, this should be taken just before the 
next scheduled administration of the DOAC and 
be rechecked 24 hours later. Close monitoring of 
the INR is recommended within the first month of 
switching. For edoxaban, the administration of a 
half dose is recommended when VKA is started.22 
For DE, the starting time of the VKA should be 
based on CrCl as follows: 3 days if CrCl is 
>50 mL/min, 2 days if CrCl is 30–50 mL/min, and 
1 day if CrCl is 15–30 mL/min.29,30 
When switching from DOAC to parenteral 
anticoagulants (LMWH or UFH), these should be 
started when the next DOAC dose is due. Inversely, 
DOAC should be started at the same time or up to 
2 hours before the next parenteral anticoagulant 
dose. For intravenous UFH, DOAC should be started 
at the time of discontinuation of the infusion.22,29 
The EMA recommends that edoxaban should be 
started 4 hours after stopping the UFH infusion.54 
The renal function should be assessed before 
switching from heparin to DOAC. 
Adherence to Bridging Procedures 
The peri-procedural interruption of DOAC 
treatment depends on the bleeding risk of the 
procedure and the patient’s thromboembolic 
risk. Interruption may require bridging therapy 
Indication Emergent 
situation†
Information required Characteristic of  
the assay
Assays recommended††
Overdose 
(without 
complication)
No Detection of 
overdose and inform 
on period at risk of 
bleeding
• Sensitive 
(qualitative and 
quantitative)
• Rapid turn-
around time
• Specific coagulation tests (i.e. 
dTT, ECA - 
dabigatran; chromogenic anti-
Xa - direct FXa inhibitors)
• Global coagulation tests (i.e. 
PT (rivaroxaban edoxaban) - 
aPTT (dabigatran) or dRVVT)
Factors 
interfering with 
pharmacokinetics 
(drug interactions, 
renal or hepatic 
impairment, genetic 
polymorphism)
No Ensure on-therapy 
level and exclude too 
low or too high drug 
levels
• Accurate 
quantitative test
• Specific coagulation tests 
(i.e. dTT, ECA - dabigatran; 
chromogenic anti-Xa - direct 
FXa inhibitors)
†Emergency situations are those in which anticoagulant effects should be measured within 30 minutes. 
††Assays recommended are presented from the more to the less suitable among those able to respond 
the clinical need.
‡The assessment will depend on the type of procedure.
aPTT: activated partial thromboplastin time; dRVVT: dilute Russell’s Viper Venom Time; dTT: dilute 
thrombin time; ECA: ecarin chromogenic assays; PT: prothrombin time; FXa: factor Xa.
Table 3 continued.
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